Millard Collins, MD
Family Medicine · Nashville, TNNPI 1952389173
Payments from drug & device makers
Across 57 payments — averaging $29.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$341
- Otsuka America Pharmaceutical, Inc.$212
- Pfizer$207
- Neurocrine Biosciences, Inc.$158
- Alkermes, Inc.$111
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$63
- plus $588 from 20 others
What the payments were for
- Food & beverage$1,680100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 2 | $341 |
| Otsuka America Pharmaceutical, Inc. | 5 | $212 |
| Pfizer | 10 | $207 |
| Neurocrine Biosciences, Inc. | 3 | $158 |
| Alkermes, Inc. | 5 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $63 |
| AbbVie | 2 | $59 |
| Johnson & Johnson(2 entities) | 3 | $54 |
| Neurelis, Inc. | 3 | $54 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| Novo Nordisk | 2 | $42 |
| AstraZeneca | 2 | $37 |
| Kerecis Limited | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Bayer | 1 | $21 |
| Novartis | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| GSK | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Urovant Sciences Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,680 in reported general payments places this provider in the 65th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 172 | $298,555 |
| EliquisApixaban | 1,701 | $265,432 |
| IngrezzaValbenazine Tosylate | 20 | $169,863 |
| Enbrel SureclickEtanercept | 11 | $87,779 |
| NuplazidPimavanserin Tartrate | 68 | $82,339 |
| XareltoRivaroxaban | 387 | $63,968 |
| XifaxanRifaximin | 52 | $45,542 |
| PerserisRisperidone | 18 | $45,469 |
| OzempicSemaglutide | 37 | $37,618 |
| JanuviaSitagliptin Phosphate | 254 | $37,029 |
| Pantoprazole Sodium | 2,284 | $33,722 |
| Atorvastatin Calcium | 4,641 | $32,586 |
| Risperdal ConstaRisperidone Microspheres | 27 | $31,920 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $29,643 |
| MyrbetriqMirabegron | 244 | $28,386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $207 | $265,4321,701 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $158 | $169,86320 claims |
| Johnson & JohnsonXarelto, Risperdal Consta, Invega Sustenna | $54 | $120,996427 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $17 | $46,59097 claims |
| Novo NordiskOzempic | $42 | $37,61837 claims |
| Lilly USA, LLCTrulicity | $18 | $21,75121 claims |
| AstraZenecaFarxiga | $37 | $21,189138 claims |
| AbbVieLinzess | $59 | $15,51027 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $212 | $14,88543 claims |
| Sanofi-aventis U.S. LLCLantus | $24 | $13,367172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Nashville
- Hina BudhwaniNashville$4.7M
- Bridgette FraneyNashville$2M
- James MosleyNashville$85K
- Keren HolmesNashville$58K
- Burton SandersNashville$19K
- Julia GomezNashville$18K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Paul WakefieldKnoxville$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.